Previous 10 | Next 10 |
A group of pharma companies focused on ant-TIGIT class of drugs are trading sharply lower in the pre-market Wednesday after French pharma giant Roche (OTCQX:RHHBY) (OTCQX:RHHBF) announced that a similar treatment failed in a late-stage trial for non-small cell lung cancer (NSCLC). The global ...
Arcus Biosciences press release (NYSE:RCUS): Q1 GAAP EPS of -$0.96 misses by $0.17. Revenue of $18.01M (+90.4% Y/Y) misses by $9.99M. Cash, cash equivalents and investments were $1.34B as of March 31, 2022, compared to $681.3M as of December 31, 2021. The increase was primarily due to the rec...
In a third interim analysis for the randomized Phase 2 ARC-7 study, both anti-TIGIT domvanalimab-containing arms continued to show meaningful differentiation compared to the anti-PD1 antibody zimberelimab alone when given as a treatment for first-line metastatic non-small cell lung ...
ADES, AGM, AIV, AKBA, ALCO, ALTO, AMC, AMPH, AMWL, ANGI, APPF, APTO, ARCT, AROC, ASLE, ASRT, ATER, AVIR, AZTA, BATL, BHF, BLFS, BLI, BLNK, BODY, OTCPK:BOWFF, BRMK, BRT, BW, BWXT, CAPL, CARA, CARG, CHMI, CLAR, CLOV, CNNE, CSTL, OTCPK:CURLF, DDD, DHT, DNB, ENTA, EQH, EVBG, FCRD, FF, FGEN, FLL, ...
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, today announced it will report financial results and key pipeline updates for the first quarter ended March ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips Arcus Biosciences (NYSE: RCUS ): Cancer biotech having multiple big-pharma collaborations that ensure revenue streams Vir Biotechnology (NASDAQ: VIR ): Diversified infectious disease play BioNTech (N...
Gainers: Sunshine Biopharma (SBFM) +181%. Nano-X Imaging (NNOX) +15%. Arcus Biosciences (RCUS) +13%. Cue Biopharma (CUE) +11%. Dermata Therapeutics (DRMA) +6%. Losers: IMARA (IMRA) -35%. GBS (GBS) -15%. Precipio (PRPO) -13%. Cassava Sciences (SAVA) -10%...
Carnival (NYSE:CCL) provided one of the highlights of Tuesday's pre-market trading. Shares rose after the cruise company signaled a continued recovery in the travel space following the pandemic shutdowns. Arcus Biosciences (RCUS) also rallied before the opening bell, boosted by news that it w...
Sunshine Biopharma (SBFM) +119% newly designed mRNA molecules prove effective against multidrug resistant cancer cells. System1 (SST) +26%. Recon Technology (RCON) +23%. Aterian (ATER) +13%. Guardforce AI (GFAI) +12% on expanding applications of robotics solutions. Arcus Biosci...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips It’s time to start off another busy day of trading with the biggest pre-market stock movers for Tuesday! Source: f11photo/Shutterstock.com New test flights, an uplisting, and a failed merger are just some of ...
News, Short Squeeze, Breakout and More Instantly...
Arcus Biosciences Inc. Company Name:
RCUS Stock Symbol:
NYSE Market:
Arcus Biosciences Inc. Website:
Arcus Biosciences (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing differentiated molecules and combination therapies for people with cancer, announced that its management team will host a conference call and webcast on Thursday, August 8 th , 2024 at 2 PM...
Arcus Biosciences, Inc. (NYSE:RCUS) and Taiho Pharmaceutical Co., Ltd. (“Taiho”) today announced that Taiho exercised its option for quemliclustat (International Nonproprietary Name; development code: AB680), an investigational small molecule CD73 inhibitor, in Japan and certain oth...
Domvanalimab is the only anti-TIGIT antibody in Phase 3 for upper gastrointestinal (GI) adenocarcinomas with the potential to be first-to-market for this patient population Arcus Biosciences, Inc. (NYSE:RCUS), a clinical-stage, global biopharmaceutical company focused on developing di...